Compare GPMT & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GPMT | PDSB |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | United States | United States |
| Employees | 28 | 10 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.9M | 62.0M |
| IPO Year | N/A | 2015 |
| Metric | GPMT | PDSB |
|---|---|---|
| Price | $1.38 | $0.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $3.00 | ★ $9.00 |
| AVG Volume (30 Days) | 173.0K | ★ 494.7K |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | ★ 12.99% | N/A |
| EPS Growth | N/A | ★ 28.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $458.85 | N/A |
| Revenue Next Year | $8.63 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.24 | $0.51 |
| 52 Week High | $3.12 | $1.55 |
| Indicator | GPMT | PDSB |
|---|---|---|
| Relative Strength Index (RSI) | 42.63 | 32.25 |
| Support Level | $1.24 | $0.73 |
| Resistance Level | $1.57 | $1.16 |
| Average True Range (ATR) | 0.07 | 0.07 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 26.53 | 9.08 |
Granite Point Mortgage Trust Inc focuses on directly originating, investing in, and managing senior floating rate commercial mortgage loans and other debt and debt-like commercial real estate investments. The company constructs its investment portfolio on a loan-by-loan basis, emphasizing rigorous credit underwriting, selectivity, and diversification, and assesses each investment from a fundamental value perspective relative to other opportunities available in the market. It typically provides intermediate-term bridge or transitional financing for a variety of purposes, including acquisitions, recapitalizations, refinancing, and a range of business plans, including lease-up, renovation, repositioning and repurposing of the commercial property.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.